Uniwersyteckie Centrum Medycyny Morskiej I Tropikalnej

The medical center is at the forefront of cardiovascular medicine, focusing on innovative treatments for acute heart failure. Through rigorous clinical trials, the center explores the efficacy of novel therapeutic agents like dapagliflozin in improving patient outcomes.

• Acute Heart Failure Management
• Cardiovascular Event Prevention
• Thrombolysis in Myocardial Infarction

By initiating treatment during hospitalization, the center aims to reduce the incidence of cardiovascular death and worsening heart failure, setting new standards in patient care.

Specializing in the intersection of mental health and heart disease, the center investigates the impact of sertraline on anxiety-depressive symptoms in patients with heart failure and preserved ejection fraction. This research is pivotal in understanding the role of mental health in cardiovascular conditions.

• Endothelial Dysfunction
• Biomarkers in Heart Failure
• Mental Health in Cardiovascular Disease

The center's work in this field aims to improve quality of life and reduce hospitalizations, highlighting the importance of comprehensive care in heart failure management.

Focusing on the use of SGLT-2 inhibitors like empagliflozin and dapagliflozin, the center conducts research to enhance outcomes for patients with acute/decompensated heart failure. This includes patients with varying ejection fractions and diabetes status.

• Heart Failure with Reduced Ejection Fraction (HFrEF)
• Heart Failure with Mid-Range Ejection Fraction (HFmEF)
• Heart Failure with Preserved Ejection Fraction (HFpEF)

By comparing the effects of these inhibitors, the center contributes to a deeper understanding of heart failure treatment, aiming to tailor therapies to individual patient needs.